17.07.2024 12:27:48
|
Johnson & Johnson Q2 Profit Decreases, But Beats Estimates
(RTTNews) - Johnson & Johnson (JNJ) released earnings for second quarter that decreased from last year but beat the Street estimates.
The company's bottom line came in at $4.69 billion, or $1.93 per share. This compares with $5.38 billion, or $2.05 per share, in last year's second quarter.
Excluding items, Johnson & Johnson reported adjusted earnings of $6.84 billion or $2.82 per share for the period.
Analysts on average had expected the company to earn $2.70 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 4.3% to $22.45 billion from $21.52 billion last year.
Johnson & Johnson earnings at a glance (GAAP) :
-Earnings (Q2): $4.69 Bln. vs. $5.38 Bln. last year. -EPS (Q2): $1.93 vs. $2.05 last year. -Revenue (Q2): $22.45 Bln vs. $21.52 Bln last year.
-Guidance: Full year EPS guidance: $9.97 - $10.07 Full year revenue guidance: $89.2 - $89.6 Bln

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
05.03.25 |
Zuversicht in New York: Dow Jones am Nachmittag freundlich (finanzen.at) | |
05.03.25 |
Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel Gewinn hätte ein Investment in Johnson Johnson von vor 10 Jahren eingebracht (finanzen.at) | |
04.03.25 |
Minuszeichen in New York: Dow Jones zum Start des Dienstagshandels im Minus (finanzen.at) | |
03.03.25 |
Verluste in New York: Dow Jones fällt zum Ende des Montagshandels zurück (finanzen.at) | |
03.03.25 |
Schwacher Handel in New York: Dow Jones sackt am Montagnachmittag ab (finanzen.at) | |
03.03.25 |
Schwacher Handel in New York: Dow Jones verliert (finanzen.at) | |
27.02.25 |
Freundlicher Handel in New York: Dow Jones am Donnerstagmittag mit Zuschlägen (finanzen.at) | |
27.02.25 |
Handel in New York: Dow Jones startet im Plus (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 153,38 | 0,42% |
|